From what 7 stock analysts predict, the share price for IDEXX Laboratories Inc (IDXX) might increase by 10.79% in the next year. This is based on a 12-month average estimation for IDXX. Price targets go from $525.00 to $675.00. The majority of stock analysts believe IDXX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
IDXX is a stock in Health Care which has been forecasted to be worth $610.71 as an average. On the higher end, the forecast price is $675.00 USD by nathan rich from Goldman Sachs and on the lower end IDXX is forecasted to be $525.00 by david westenberg from Piper Sandler.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
chris schott J.P. Morgan | Buy | $630.0 | maintained | Feb 6, 2024 |
jonathan block Stifel Nicolaus | Hold | $570.0 | rated | Feb 6, 2024 |
erin wright Morgan Stanley | Buy | $620.0 | maintained | Feb 6, 2024 |
michael ryskin Bank of America Securities | Hold | $600.0 | reiterated | Feb 5, 2024 |
balaji prasad Barclays | Buy | $655.0 | rated | Feb 5, 2024 |
nathan rich Goldman Sachs | Buy | $675.0 | reiterated | Feb 5, 2024 |
david westenberg Piper Sandler | Hold | $525.0 | downgraded | Jan 30, 2024 |
steve chesney Atlantic Equities | Hold | $600.0 | downgraded | Aug 2, 2023 |
elliot wilbur Raymond James | Hold | None | maintained | Feb 6, 2023 |
jason goldberg Barclays | Buy | $582.0 | rated | Jan 16, 2023 |
andrew cooper Raymond James | Hold | None | reiterated | Feb 2, 2021 |
rob eich Cleveland Research | Hold | None | maintained | Apr 27, 2020 |
mark massaro BTIG | Buy | $315.0 | maintained | Oct 31, 2019 |
ryan daniels William Blair | Buy | None | maintained | Oct 24, 2019 |
john ransom Raymond James | Hold | None | maintained | Aug 17, 2018 |
nicholas jansen Raymond James | Hold | None | maintained | Feb 6, 2018 |
derik de bruin Bank of America Securities | Buy | $220.0 | maintained | Feb 2, 2018 |
alexander nowak Craig-Hallum | Buy | $211.0 | maintained | Feb 1, 2018 |
kevin ellich Craig-Hallum | Hold | $75.0 | maintained | Feb 1, 2016 |
david clair Piper Sandler | Hold | $126.0 | rated | Jul 28, 2014 |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
When did it IPO
1991
Staff Count
11,000
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Jonathan J. Mazelsky
Market Cap
$46.14B
In 2023, IDXX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IDXX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
$423.45
DXCM-USD
$116.39
PAYX-USD
$123.38
MCHP-USD
$81.61
$103.34
$82